Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott increases investment in SpectRx:

This article was originally published in Clinica

Executive Summary

Abbott Laboratories has increased its shareholding in the non-invasive glucose monitor developer, SpectRx, of Norcross, Georgia, by buying $2.75 million in preferred shares with a further $2.5 million commitment in January under the same terms. The revised agreement for the continuous monitoring device, presently in prototype form, gives Abbott exclusive worldwide marketing rights. SpectRx gets new milestones and will get a royalty on disposables when the product is eventually launched.

You may also be interested in...



Brexit: New Rules Will Hit Parallel Trade From UK to EU

Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway 

Health And Wellness Trademark Review 24 November, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Post-Brexit MHRA Will Embrace Medtech ‘Innovation Pull’ In The UK

The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel